Plasminogen-activator inhibitor-1 polymorphisms are associated with obesity and fat distribution in the Québec Family Study: Evidence of interactions with menopause

Menopause

Volumn 12, Issue 2, 2005, Pages 136-143

  Bouchard, Luigi ^a   Mauriège, Pascale ^a   Vohl, Marie Claude ^a   Bouchard, Claude ^b   Pérusse, Louis ^a  

^a UNIVERSITÉ LAVAL   (Canada)

^b PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

Author keywords

Abdominal obesity; Mutation; PAI1; Visceral fat

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADOLESCENT; ADULT; AGED; ARTICLE; BODY FAT; BODY MASS; CONTROLLED STUDY; DNA POLYMORPHISM; EXON; FEMALE; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; MALE; MENOPAUSE; OBESITY; POSTMENOPAUSE; PROMOTER REGION; STATISTICAL ANALYSIS;

ADIPOSE TISSUE; ADOLESCENT; ADULT; AGED; BODY COMPOSITION; BODY MASS INDEX; COHORT STUDIES; DNA PRIMERS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; MALE; MIDDLE AGED; OBESITY; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POSTMENOPAUSE; PROMOTER REGIONS (GENETICS); QUEBEC;

EID: 16244368062     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042192-200512020-00006     Document Type: Article

References (58)

1. Björntorp P. Visceral obesity: a "civilization syndrome." Obes Res 1993;1:206-222.
2. Kissebah AH, Krakower GR. Regional adiposity and morbidity. Physiol Rev 1994;74:761-811.
3. Bouchard C, Tremblay A, Després JP, et al. The response to long-term overfeeding in identical twins. N Engl JMed 1990;322:1477-1482.
4. Chagnon YC, Rankinen T, Snyder EE, Weisnagel SJ, Pérusse L, Bouchard C. The human obesity gene map: the 2002 update. Obes Res 2003;11:313-367.
5. Pouliot MC, Després JP, Nadeau A, et al. Associations between regional body fat distribution, fasting plasma free fatty acid levels and glucose tolerance in premenopausal women. Int J Obes 1990;14:293-302.
6. Terry RB, Stefanick ML, Haskell WL, Wood PD. Contributions of regional adipose tissue depots to plasma lipoprotein concentrations in overweight men and women: possible protective effects of thigh fat. Metabolism 1991;40:733-740.
7. Gordon T, Kannel WB, Hjortland MC, McNamara PM. Menopause and coronary heart disease. The Framingham Study. Ann Intern Med 1978;89:157-161.
8. Heymsfield SB, Gallagher D, Poehlman ET, et al. Menopausal changes in body composition and energy expenditure. Exp Gerontol 1994;29:377-389.
9. Frühbeck G, Gomez-Ambrosi J, Muruzabal FJ, Burrell MA. The adipocyte: a model for integration of endocrine and metabolic signaling in energy metabolism regulation. Am J Physiol Endocrinol Metal 2001;280:E827-E847.
10. Simpson AJ, Booth NA, Moore NR, Bennett B. Distribution of plasminogen activator inhibitor (PAI-1) in tissues. J Clin Pathol 1991;44:139-143.
11. Alessi MC, Peiretti F, Morange P, Henry M, Nalbone G, Juhan-Vague I. Production of plasminogen activator inhibitor 1 by human adipose tissue: possible link between visceral fat accumulation and vascular disease. Diabetes 1997;46:860-867.
12. Binder B, Christ G, Gruber F, et al. Plasminogen activator inhibitor 1: physiological and pathophysiological roles. News Physiol Sci 2002;17:56-61.
13. Bastelica D, Morange P, Berthet B, et al. Stromal cells are the main plasminogen activator inhibitor-1-producing cells in human fat: evidence of differences between visceral and subcutaneous deposits. Arterioscler Thromb Vasc Biol 2002;22:173-178.
14. Vague P, Juhan-Vague I, Aillaud MF, et al. Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level, and relative body weight in normal and obese subjects. Metabolism 1986;35:250-253.
15. Koh KK, Mincemoyer R, Bui MN, et al. Effects of hormone-replacement therapy on fibrinolysis in postmenopausal women. N Engl J Med 1997;336:683-690.
16. Hamsten A, de Faire U, Walldius G, et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987;2:3-9.
17. Juhan-Vague I, Alessi MC. PAI-1, obesity, insulin resistance and risk of cardiovascular events. Thromb Haemost 1997;78:656-660.
18. van Harmelen V, Wahrenberg H, Eriksson P, Arner P. Role of gender and genetic variance in plasminogen activator inhibitor-1 1 secretion from human adipose tissue. Thromb Haemost 2000;83:304-308.
19. Hoffstedt J, Andersson L, Persson L, Isaksson B, Arner P. The common-675 4G/5G polymorphism in the plasminogen activator inhibitor-1 gene is strongly associated with obesity. Diabetologia 2002;45:584-587.
20. Freeman M, Mansfield M. To: J. Hoffstedt et al. (2002) The common-675 4G/5G polymorphism in the plasminogen activator inhibitor-1 gene is strongly associated with obesity. Diabetologia 2002;45:1602-1603.
21. Bouchard C. Genetic epidemiology, association and sib-pair linkage: results from the Québec Family Study. In: Bray G, Ryan D, eds. Molecular and Genetic Aspects of Obesity. Baton Rouge, LA: Louisiana State University Press, 1996:470-481.
22. Behnke A, Wilmore W. Evaluation and Regulation of Body Built and Composition. Englewood Cliffs, NJ: Prentice-Hall, 1974.
23. Siri W. The gross composition of the body. In: Lawrence JH, Tobias CA, ed. Advances in Biological and Medical Physics. New York: Academic Press, 1976:239-280.
24. Pérusse L, Rice T, Chagnon YC, et al. A genome-wide scan for abdominal fat assessed by computed tomography in the Québec Family Study. Diabetes 2001;50:614-621.
25. Sun X, Ding H, Hung K, Guo B. A new MALDI-TOF based mini-sequencing assay for genotyping of SNPS. Nucleic Acids Res 2000;28:E68.
26. Huber P. Proceedings of the 5th Berkeley Symposium on Mathematical Statistics and Probability. Berkeley, CA: University of California Press, 1967.
27. White M. A heteroskedasticity-consistent covariance matrix estimator and a direct test for heteroskedasticity. Econometrica 1980;48:817-838.
28. Morange PE, Henry M, Tregouet D, et al. The A-844G polymorphism in the PAI-1 gene is associated with a higher risk of venous thrombosis in factor V Leiden carriers. Arterioscler Thromb Vasc Biol 2000;20:1387-1391.
29. Menges T, Hermans PW, Little SG, et al. Plasminogen-activator-inhibitor-1 4G/5G promoter polymorphism and prognosis of severely injured patients. Lancet 2001;357:1096-1097.
30. Morange PE, Lijnen HR, Alessi MC, Kopp F, Collen D, Juhan-Vague I. Influence of PAI-1 on adipose tissue growth and metabolic parameters in a murine model of diet-induced obesity. Arterioscler Thromb Vasc Biol 2000;20:1150-1154.
31. Schafer K, Fujisawa K, Konstantinides S, Loskutoff DJ. Disruption of the plasminogen activator inhibitor 1 gene reduces the adiposity and improves the metabolic profile of genetically obese and diabetic ob/ob mice. Faseb J 2001;15:1840-1842.
32. Lijnen H, Maquoi E, Morange P, et al. Nutritionally induced obesity is attenuated in transgenic mice overexpressing plasminogen activator inhibitor-1. Arterioscler Thromb Vasc Biol 2003;23:78-84.
33. Carmeliet P, Collen D. Gene targeting and gene transfer studies of the biological role of the plasminogen/plasmin system. Thromb Haemost 1995;74:429-436.
34. De Pergola G, De Mitrio V, Giorgino F, et al. Increase in both prothrombotic and anti-thrombotic factors in obese premenopausal women: relationship with body fat distribution. Int J Obes Relat Metab Disord 1997;21:527-535.
35. De Pergola G, De Mitrio V, Sciaraffia M, et al. Lower androgenicity is associated with higher plasma levels of prothrombotic factors irrespective of age, obesity, body fat distribution, and related metabolic parameters in men. Metabolism 1997;46:1287-1293.
36. Henry M, Tregouet DA, Alessi MC, et al. Metabolic determinants are much more important than genetic polymorphisms in determining the PAI-1 activity and antigen plasma concentrations: ;a family study with part of the Stanislas Cohort. Arterioscler Thromb Vasc Biol 1998;18:84-91.
37. Festa A, D'Agostino R, Rich S, Jenny N, Tracy R, Haffher S. Promoter (4G/5G) plasminogen activator inhibitor-1 genotype and plasminogen activator inhibitor-1 levels in blacks, Hispanics, and non-Hispanic whites: the Insulin Resistance Atherosclerosis Study. Circulation 2003;107:2422-2427.
38. Eriksson P, Kallin B, van't Hooft FM, Bavenholm P, Hamsten A. Allele-specific increase in basal transcription of the plasminogen-1 activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci USA 1995;92:1851-1855.
39. Henry M, Chomiki N, Scarabin PY, et al. Five frequent polymorphisms of the PAI-1 gene: lack of association between genotypes, PAI activity, and triglyceride levels in a healthy population. Arterioscler Thromb Vasc Biol 1997;17:851-858.
40. Wiman B, Chmielewska J, Ranby M. Inactivation of tissue plasminogen activator in plasma. Demonstration of a complex with a new rapid inhibitor. J Biol Chem 1984;259:3644-3647.
41. Kluft C, Jie AF, Rijken DC, Verheijen JH. Daytime fluctuations in blood of tissue-type plasminogen activator (t-1 PA) and its fast-acting inhibitor (PAI-1). Thromb Haemost 1988;59:329-332.
42. Angleton P, Chandler WL, Schmer G. Diurnal variation of tissue-type plasminogen activator and its rapid inhibitor (PAI-1). Circulation 1989;79:101-106.
43. Koistinen HA, Dusserre E, Ebeling P, Valuer P, Koivisto VA, Vidai H. Subcutaneous adipose tissue expression of plasminogen activator inhibitor-1 (PAI-1) in nondiabetic and Type 2 diabetic subjects. Diabetes Metab Res Rev 2000;16:364-369.
44. Maemura K, de la Monte SM, Chin MT, et al. CLIF, a novel cycle-like factor, regulates the circadian oscillation of plasminogen activator inhibitor-1 aene expression. J Biol Chem 2000;275:36847-36851.
45. Van Der Bom JG, Bots ML, Haverkate F, Kluft C, Grobbee DE. The 4G5G polymorphism in the gene for PAI-1 and the circadian oscillation of plasma PAI-1. Blood 2002;24:1841-1844.
46. Banfi CEP, Giandomenico G, Mussoni L, Sironi L, Hamsten A, Tremoli E. Transcriptional regulation of plasminogen activator inhibitor type 1 gene by insulin: insights into the signaling pathway. Diabetes 2001;50:1522-1530.
47. Halleux CM, Declerck PJ, Tran SL, Detry R, Brichard SM. Hormonal control of plasminogen activator inhibitor-1 gene expression and production in human adipose tissue: stimulation by glucocorticoids and inhibition by catecholamines. J Clin Endocrinol Metab 1999;84:4097-4105.
48. Chandler WL, Mornin D, Whitten RO, et al. Insulin, cortisol and catecholamines do not regulate circadian variations in fibrinolytic activity. Thromb Res 1990;58:1-12.
49. Moe KE. Reproductive hormones, aging, and sleep. Semin Reprod Endocrinol 1999;17:339-348.
50. He G, Pedersen SB, Bruun JM, Richelsen B. Regulation of plasminogen activitor inhibitor-1 in human adipose tissue: interaction between cytokines, cortisol and estrogen. Horm Metab Res 2000;32:515-520.
51. Grancha S, Estelles A, Tormo G, et al. Plasminogen activator inhibitor-1 (PAI-1) promoter 4G/5G genotype and increased PAI-1 circulating levels in postmenopausal women with coronary artery disease. Thromb Haemost 1999;81:516-521.
52. Brown N, Abbas A, Byrne D, Schoenhard J, Vaughan D. Comparative effects of estrogen and angiotensin-converting enzyme inhibition on plasminogen activator inhibitor-1 in healthy post-menopausal women. Circulation 2002;105:304-309.
53. Fletcher SW, Colditz GA. Failure of estrogen plus progestin therapy for prevention. JAMA 2002;288:366-368.
54. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Miletich JR Arterial and venous thrombosis is not associated with the 4G/5G polymorphism in the promoter of the plasminogen activator inhibitor gene in a large cohort of US men. Circulation 1997;95:59-62.
55. Roest M, van der Schouw YT, Banga JD, et al. Plasminogen activator inhibitor 4G polymorphism is associated with decreased risk of cerebrovascular mortality in older women. Circulation 2000;101:67-70.
56. Yamada Y, Izawa H, Ichihara S, et al. Prediction of the risk of myocardial infarction from polymorphisms in candidate genes. N Engl J Med 2002;347:1916-1923.
57. Leander K, Wiman B, Hallqvist J, Sten-Linder M, de FU. PAI-1 level and the PAI-1 4G/5G polymorphism in relation to risk of non-fatal myocardial infarction. Thromb Haemost 2003;89:1064-1071.
58. Mannucci PM, Mari D, Merati G, et al. Gene polymorphisms predicting high plasma levels of coagulation and fibrinolysis proteins. A study in centenarians. Arterioscler Thromb Vasc Biol 1997;17:755-759.